5762-40-3Relevant articles and documents
PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
-
Paragraph 0483-0486, (2021/08/13)
The disclosure provides processes for preparing a compound of Formula (I).
SOLID FORMS OF MODULATORS OF CFTR
-
Paragraph 00242, (2020/10/27)
Crystalline and amorphous forms of a potassium salt of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
METHODS OF TREATMENT FOR CYSTIC FIBROSIS
-
Paragraph 00194-00195, (2020/12/11)
This application describes methods of treating cystic fibrosis comprising administering Compound I:, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising any of the foregoing.
COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS
-
Paragraph 00291; 00292; 00293; 00294, (2019/01/22)
Compositions comprising Compound I of the formula (I) and methods of treating cystic fibrosis comprising administering Compound I. Compositions comprising a pharmaceutically acceptable salt of Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of Compound I.
METHODS OF TREATMENT FOR CYSTIC FIBROSIS
-
Paragraph 00146-00147, (2019/02/06)
Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.
CRYSTALLINE FORMS OF MODULATORS OF CFTR
-
Paragraph 00403, (2019/10/19)
Crystalline Forms of Compound (I); crystalline Forms of Compound (II) and crystalline forms of pharmaceutically acceptable salts of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
-
Paragraph 0515-0517, (2019/08/20)
A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
-
Paragraph 00158, (2019/10/29)
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical composi
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR
-
Paragraph 00158, (2019/11/04)
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis by administering such modulators and pharmaceutical compositions, and processes for making such modulators.
CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
-
Paragraph 0459; 0460; 0461, (2019/05/07)
Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereofare disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
